



## Corrigendum

Following publication of the article, 'The association between depot medroxyprogesterone acetate and meningiomas: Emerging data and their relevance to the South African context'<sup>[1]</sup> the *SAMJ* was notified that the conflict of interest statement was incomplete in the published version.

The conflict of interest statement should read as follows:

**Conflicts of interest.** RdW and MB co-chair the National Essential Medicines List Committee (NEMLC). KC is a member of the Expert Review Committee of the NEMLC. MB is the chair of the SAHPRA Pharmacovigilance Committee. KC is a member of the SAHPRA Pharmacovigilance Committee. This work is the responsibility of the authors, and does not necessarily represent the official views of the NEMLC or SAHPRA. As of 12 December 2025, SJ has been contracted by DLA Piper Global Law Firm to give expert opinion on intracranial meningiomas, which has had no bearing on the content presented in this manuscript.

The online version of the article has been updated to reflect this information.

The authors apologise for this omission.

1. Burman RJ, de Waal R, Cohen K, et al. The association between depot medroxyprogesterone acetate and meningiomas: Emerging data and their relevance to the South African context. *S Afr Med J* 2026;116(1):e4529. <https://doi.org/10.7196/SAMJ.2026.v116i1.4529>

*S Afr Med J* 2026;116(3):e5029. <https://doi.org/10.7196/SAMJ.2025.v116i3.5029>